Here, we used an established partial LOF mutation in TYK2 (rs34536443), previously shown to protect against psoriasis and other autoimmune diseases,6, 7 to evaluate the potential effect of therapeutic TYK2 inhibition on risk of lung cancer and non‐Hodgkin lymphoma. The gene discussed is TYK2; the disease is psoriasis.